Aurora Value Chain Analysis
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Explore the Complete Value Chain Behind the Preview
This Aurora Value Chain Analysis gives you a clear, company-specific view of how Aurora creates value through its support and primary activities. The page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Support Activities
Firm Infrastructure
Aurora's firm infrastructure is built for global compliance, with centralized finance and quality control spanning 15 international medical markets. In fiscal 2025, Aurora reported net revenue of about CA$343 million and kept EU-GMP-aligned operations in place, which helps it handle filings, audits, and product releases with tighter control. That setup supports disciplined cash management and lowers the risk of regulatory slips in a highly regulated business.
Human Resource Management
Aurora Cannabis' 2025 workforce model favors specialists in pharmaceutical manufacturing and horticultural science, not mass labor. Its fiscal 2025 net revenue was C$343.5 million, so training is built around high-precision processing and global safety rules for controlled substances. A lean team of skilled technicians and clinical educators helps keep labor costs tight while supporting regulated medical markets.
Technology Development
In fiscal 2025, Aurora Value Chain Analysis's technology development centered on proprietary genomic breeding and hybrid greenhouses with automated climate control, helping produce high-yield cultivars and tighter batch consistency. The company says its medical flower can be up to 20% more potent, a gain that supports premium pricing and lower waste. This R&D-heavy model underpins more efficient output in a C$315 million-revenue business.
Procurement
In fiscal 2025, Aurora's procurement focused on bulk sourcing of premium agricultural inputs and pharma-grade packaging to cut unit costs. It also used global logistics partners for cold-chain materials and secure containers, which matters for long-haul exports. These vendor controls helped keep about 95% of production inputs within strict quality standards before they reached the cultivation floor.
Aurora's Lean, Compliance-First Support Engine Boosts Efficiency
In fiscal 2025, Aurora Cannabis' support activities stayed lean and compliance-heavy: centralized infrastructure backed CA$343.5 million in net revenue, specialist staff kept pharma-grade production tight, and R&D focused on genomic breeding and automated greenhouses. Procurement also stayed disciplined, using quality-controlled inputs and logistics partners to protect batch consistency and export flow. These support functions helped Aurora manage regulated medical markets with lower waste and tighter cost control.
What is included in the product
Detailed Word Document
Editable Excel File
Primary Activities
Inbound Logistics
In FY2025, Aurora's inbound logistics centers on secure, climate-controlled intake of high-grade nutrients and proprietary genetics, which protects plant quality before production starts. Specialized receiving controls document every seed or clone batch, so genetic pedigree and quality checks stay traceable end to end. That traceability supports a tighter medical supply chain and lowers the risk of contamination or batch loss.
Operations
Aurora Cannabis runs cultivation in controlled facilities with automated irrigation and light-deprivation systems, then turns harvested biomass into high-purity oils, softgels, and flower in pharmaceutical-grade extraction labs. In fiscal 2025, the Company reported net revenue of about C$314.5 million, showing that this medical-specification production model still supports scale. Its process is built to keep output aligned with medical standards, no matter the final channel.
Outbound Logistics
Aurora's outbound logistics supports a wide export network across North America and Europe, with customs and secure transport built for high-value medical cannabis. In fiscal 2025, Aurora reported net revenue of about C$350 million, showing scale behind these flows. Cold-chain shipping helps preserve cannabinoid stability for pharmacy channels in Germany and Australia. Tight inventory control also cuts storage costs while keeping clinical prescription orders moving fast.
Marketing and Sales
Aurora's marketing and sales focus on clinical detailing and medical educator outreach, especially in Europe and Canada, to win doctor-prescribed use. In fiscal 2025, its medical channel supported nearly 80,000 registered patients, which helps drive higher-margin sales by framing Aurora as a science-led chronic care brand.
Digital platforms and partner portals also simplify direct ordering, so the company can convert medical demand faster than with retail-only selling. Recreational sales still add volume, but the medical mix is the key margin lever.
Service
In fiscal 2025, Aurora Value Chain Analysis service activity centers on post-sale patient support, with teams guiding authorized users on product titration and possible medical interactions. Its patient portals add tracking tools and dosage logs, which helps improve safety, adherence, and clinical follow-up. This support also strengthens retention and helps Aurora meet global pharmacovigilance rules.
Aurora FY2025: Medical Cannabis Growth, C$350M Revenue
Aurora's primary activities in FY2025 focused on controlled cultivation, pharmaceutical-grade extraction, and medical-market distribution. The Company served nearly 80,000 registered patients and reported about C$350 million in net revenue, with medical sales still the main value driver. Its outbound logistics and post-sale support were built for regulated cross-border supply and patient adherence.
| FY2025 metric | Value |
|---|---|
| Net revenue | C$350 million |
| Registered patients | Nearly 80,000 |
Preview the Actual Deliverable
Aurora Reference Sources
This preview shows the actual Aurora Value Chain Analysis document you'll receive after purchase – no sample, no placeholders. What you see here is pulled directly from the full report, with the same structure, insights, and professional formatting. Once checkout is complete, the full version is unlocked for immediate download.
Frequently Asked Questions
Aurora utilizes a network of EU-GMP certified facilities to distribute products to 15 different international markets. By securing 3 key certifications, they maintain a first-mover advantage in high-barrier regions like Germany and Australia. These medical-grade facilities ensure that 95 percent of shipments meet rigorous pharmaceutical standards, driving their premium revenue segment.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.